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Leishmaniases are parasitic diseases that spread in many countries with a prevalence of 12 million cases. There are few available
treatments and antimonials are still of major importance in the therapeutic strategies used in most endemic regions. However,
resistancetowardthesecompoundshasrecentlyemergedinareaswherethereplacementofthesedrugsismainlylimitedbythecost
ofalternativemolecules.Inthispaper,wereviewedthestudiescarriedoutonantimonialresistanceinLeishmania.Severalcommon
limitations of these works are presented before prevalent approaches to evidence antimonial resistance are related. Afterwards,
phenotypic determination of resistance is described, then confronted to clinical outcome. Finally, we detail molecular mechanisms
and targets involved in resistance and already identiﬁed in vitro within selected mutant strains or in clinical isolates.
1.Introduction
Leishmaniases are a set of vector-borne diseases caused by
a ﬂagellate protozoan transmitted by the bite of an insect
vector, the phlebotomine sandﬂy. This group of diseases
aﬀects 98 countries with three distinct entities: cutaneous,
mucocutaneous, and visceral leishmaniasis [1]. Various
clinical outcomes are described from a simple skin lesion
that may heal spontaneously to a multi-organ failure, fatal
if untreated. There is still no human vaccine against this
disease [2] and therapy takes a major place in the control
strategies. Moreover, there are few drugs available and their
eﬀectiveness is variable. The use of the liposomal form
of amphotericin B, a highly active molecule with reduced
side eﬀects, is still restricted to the treatment of visceral
leishmaniasis in countries that can aﬀord its cost, such
as European countries. However Europe accounts for less
than 1% of the approximately 500,000 cases per year which
occur mainly in the Indian subcontinent, Sudan, and Brazil
[3]. Other molecules such as pentamidine, miltefosine, or
ﬂuconazole are available but their use is restricted owing
to side eﬀects, cost, or eﬀectiveness [4]. This accounts for
the still predominant place of antimony derivatives, sodium
stibiogluconate (Pentostam), and meglumine antimoniate
(Glucantime) which have been used in the treatment of
the majority of cases of leishmaniases for more than 60
years worldwide. Currently, these molecules have two major
limitations: ﬁrst, side eﬀe c t sa r ef r e q u e n ta n dc a nb es e r i o u s ;
second, parasite resistance is emerging in some endemic
areas, causing an increase in treatment failure [5, 6]. Resis-
tance to antimonials has emerged over 20 years in the region
of Bihar in India. Low dosage or insuﬃcient duration of
treatment led to the selection of resistant mutants that were
transmitted more easily in this anthroponotic form than in
areas where anthropozoonotic cycle occurs. Currently, in the
most heavily aﬀectedareas of India, resistance to antimonials
may reach more than 60% of the cases, thus representing
a public health problem [7]. It imposed the use of other
drugssuchasamphotericine Bor,morerecently,miltefosine.
Other endemic areas such as Sudan are also experiencing
this phenomenon [8]. Cases of resistance have also been
described in Europe for over a decade [9]. Here the selection
occurs in dogs which, unlike men, are still being treated
with antimonials [10]. In other mediterranean areas such
as Maghreb, Albania, and Middle East except Israel, most
infected dogs are left untreated; antimonials are still the ﬁrst
line treatment and display high eﬃciency [11, 12]. The issue
of antileishmanial therapy depends on several factors such as2 Journal of Tropical Medicine
the immune status of the host, the molecule, its preparation,
its administration, and the susceptibility of the strain to the
drug [13, 14].
Drug resistance of Leishmania may be natural, acquired
whentheparasiteisexposedtosuboptimaldosesofthedrug,
or induced in vitro after selection of mutants by exposure to
gradually increasing concentrations of the drug.
This review deals with molecular mechanisms in Leish-
mania resistance to antimonials. First, we relate methodol-
ogy,generallimitations,andtoolsusedforresistancesurveys.
In a second step, we describe phenotypic determination of
resistance and its correlation with clinical outcome. Finally,
we focus on molecular resistance pathways and already
identiﬁed targets within in vitro selected mutants and ﬁeld
isolates.
2.Methodologic Aspects
Several approaches have been used to study antimony
resistance at cellular or molecular scales. They address the
phenotypic, genomic, or proteomic levels. Before discussing
the diﬀerent ways of investigation, we present some general
considerations related to Leishmania isolates, the evolution
of their characteristics during maintenance in vitro, selection
of mutants, and postulates about cross-resistance mecha-
nisms.
2.1. General Limitations
2.1.1. Parasites
(1) Leishmania Species. Several in vitro experiments were
performed on L. tarentolae, a non-infective species for
laboratory personnel [15–20]. By using this species, diﬀerent
resistance mechanisms and molecular targets were identiﬁed
andtheirpresenceconﬁrmedinotherspeciesselectedinvitro
or from clinical isolates. However, intrinsic susceptibility to
heavy metals and thiols levels found in L. tarentolae can be
very diﬀerent from those encountered in Leishmania species
of clinical interest [21].
(2) Parasitic Stage and Resistance. Most of in vitro resistance
experiments are performed on promastigotes, easier to culti-
vate and to quantify than amastigotes. However, they do not
representtheparasiticstageonwhichantimonialsactinvivo.
Promastigotes are usually not sensitive to SbV which has a
stage-speciﬁc activity unless they are exposed to PentostamR
and several experiments indicate that this susceptibility is
not due to sodium stibiogluconate but rather to chlorocresol
included in Pentostam formulation [22, 23]. Ephros et al.
showed that L. donovani axenic amastigotes were consid-
erably more susceptible to Pentostam than promastigotes.
The two stages were also tested for chlorocresol susceptibility
displaying almost the same IC50. Interestingly, chlorocresol
concentration for Pentostam IC50 was eight-fold lower than
chlorocresol IC50 in axenic amastigotes. Thus increased sus-
ceptibility of axenic amastigotes to Pentostam is mainly due
to SbV [24]. In another study, L. donovani amastigotes were
either SbIII or SbV (Glucantime or Pentostam chlorocresol
free) sensitive unlike promastigotes which displayed a very
highIC50.SusceptibilitytoSbVfollowsstagetransformation
from promastigotes to axenic amastigotes while resistance
to SbV is acquired while amastigotes diﬀerentiate into
promastigotes [25]. Promastigotes also display diﬀerent and
mostly higher thiols levels than amastigotes [26]. Carriers
belonging to the ABC system and involved in the eﬄux or
sequestration of antimonials have indeed been identiﬁed in
promastigotes resistant mutants and few studies on the role
of these proteins have been conducted on amastigotes.
(3) Selection during Treatment of the Host. The in vitro
sensitivity of strains isolated from untreated hosts did not
change despite the successive passages in culture or after
animal infection. However, the sensitivity was reduced in
strains isolated from either patients or dogs treated with
antimonials [9, 10, 27]. The growth and proliferation
of cultured strains isolated after treatment were lowered
compared to the strains isolated before treatment [27].
2.1.2. Conditions of Culture and Selection In Vitro
(1) Culture Medium. T h eg r o w t hr a t eo fL. infantum pro-
mastigotes inﬂuences their IC50 for SbV chlorocresol-free
formulations as reported by Carrio et al. In fact, diﬀerent
IC50 values can be obtained for the same strain by varying
heat-inactivated fetal calf serum concentration in culture
medium. Variation of pH can also inﬂuence promastigotes
susceptibility to SbV mostly for Schneider’s medium but also
for M199 and RPMI media [28].
( 2 )I m p a c to fI nV i t r oC u l t u r eo nP r i m a r yP h e n o t y p e . L e i s h -
mania parasites isolated from an infected host may present a
polyclonal population with a varied expression of diﬀerent
phenotypes such as growth capacity in vitro, infectivity,
and drug resistance [29, 30]. Obtaining a suﬃcient number
of promastigotes to conduct experiments often requires
numerous passages and thus can induce changes in the
expression pattern of the parasite. The possible selection of
one or some clones that were not dominant at the time
of parasite isolation may complicate the interpretation of
a resistance survey. Indeed, the virulence of a strain and
its capacity for growth and adaptation in culture can alter
the clonal composition of strain over successive passages
in the medium and so modify the expression of resistance
phenotype. However, experiments have shown that during
induction of in vitro resistance by discontinuous exposition
of parasites to the drug, the resistance phenotype does
not vary either during successive passages in culture in
the absence of the drug or after in vivo infection [29,
30]. In addition, Antimonial resistant L. donovani Indian
strains cultured with several passages before infection of
macrophages or hamsters maintained their resistance proﬁle
[31]. Molecular markers analysis directly performed from
biological samples should avoid this possible bias.
(3) Use of Arsenicals for In Vitro Selection. Several experi-
ments on Leishmania resistance were performed with a pro-
gressive selection of mutant strains by exposing promastig-
otestoincreasingconcentrationsofarsenicals[17,20,32,33].Journal of Tropical Medicine 3
These studies suﬀer the selection bias of arsenic derivatives
not used in antileishmanial therapy but whose use in vitro
showed that they confer cross-resistance to antimonials.
Arsenicals have undubitably common characteristics with
antimonialsintheirmodeofactionsuchasincreasedreactive
oxygen species (ROS), loss of mitochondrial membrane
potential and collapse of the available quantity of ATP fol-
lowed by a cell death that occurs by cell shrinkage and DNA
fragmentation. The two related heavy metals require iron for
their cytotoxic eﬀect. However, arsenicals induce an increase
inintracellularcalciumthatdoesnotoccurwithantimonials.
Conversely, the level of intracellular glutathione which is
not aﬀected during treatment with arsenicals is lowered
when antimonials are used. The inhibition of calcium inﬂux
in case of arsenicals and glutathione supplementation in
presence of antimony decreased cell death in both cases [34].
It is therefore conceivable that the mutant strains selected
in vitro against arsenic derivatives and then tested against
antimonials may have developed resistance mechanisms
speciﬁc to arsenite along with other common mechanisms,
thus explaining the phenomenon of cross-resistance.
(4) SbIII, and SbV-Selected Mutants. The use of SbIII that
is not the prescribed form in clinical practice but represents
the biologically active form of the drug would lead to the
selection of resistant strains with diﬀerent mechanisms and
targets that are not necessarily involved in clinical isolates
resistance since these are ﬁrst exposed to SbV. However,
cross-resistance between SbV, SbIII, and AsIII that was
observed in some Leishmania species such as L. tarentolae,
L. major, L. Mexicana, and L. infantum [15, 35, 36]a l l o w e d
performing resistance experiments with SbIII. However, in
some L. donovani strains, no cross-resistance was found
[25]. Experiments on L. panamensis strains from clinical
relapse showed that while amastigotes were SbV resistant,
and promastigotes were sensitive to SbIII [37].
2.2. Phenotypic Analysis of Resistance
2.2.1. Animal Model. The infection of mice or hamsters,
which was among the ﬁrst approaches for studying the
sensitivity to antimonials in vivo, still faces the problem
of variability related to the host and genetic background
of these vertebrate hosts may have a major inﬂuence
upon evolution after infection. They are currently mainly
performed for immunological or genetic studies [31, 38, 39].
2.2.2. In Vitro Macrophages Infection. Macrophages cultiva-
tion and their infection with promastigotes are useful tools
for analysing the sensitivity of amastigotes. This technique
is time consuming and it suﬀers from the variability of
infectivity due to the growth characteristics of the strain and
to in vitro metacyclogenesis level [40]. However, it remains
a reference technique for studying the resitance phenotype
of clinical isolates. Diﬀerent cell lines can be used such
as murine peritoneal exudate macrophages, murine bone
marrow-derived macrophages, human monocyte-derived
macrophages, and the human monocytic THP-1 cell line.
Recently, it has been shown that either the infection kinetics
or the activity of the drug especially antimonials depends
on the host cell type. Consequently, macrophage population
must be taken into account before any comparison between
studies and there is a need for standardization [41].
2.2.3. Axenic Amastigotes. The diﬃculty of sensitivity tests
on infected macrophages is partially overcome by the axenic
amastigotes approach, also called amastigotes-like. These
stages are obtained by gradual changes of temperature and
pH of cultured promastigotes until the parasites resemble
amastigotes and express speciﬁc proteins and morphology of
this stage [42]. Nevertheless, amastigote-like cells are hetero-
geneous and do not acquire all the characteristics of in vivo
amastigotes. Indeed ultrastructural studies indicated that
many amastigotes-like cells exhibit promastigote features
[43]. Moreover, long-term culture may lead to reappearance
of promastigote-like pattern [44]. While several studies
have used this model and highlighted axenic amastigotes
susceptibilitytoSbV[25,35],otherreportsshowedthatpen-
tavalentantimonyisinactiveontheseformsandrecommend
intracellular amastigotes as the gold standard for in vitro
sensitivity studies [42].
2.2.4. Correlation to Clinical Outcome. It is important to
assess whether in vitro tests used to determine the sensitivity
of a clinical isolate reﬂect the response to treatment and
clinical resistance. Faraut-Gambarelli et al. evidenced that in
clinical isolates, among both HIV and immunocompetent
patients, the IC50 of amastigotes within macrophages was
signiﬁcantly higher in patients who have not improved,
compared to those who have responded to treatment.
Similarly, strains from patients previously treated exhibited
higher IC50 than strains from untreated patients. There was
no diﬀerence in the IC50 for patients cured compared to
those who developed a relapse after an initial improvement
but iterative treatment with antimonials induced an increase
in IC50 in strains isolated successively from the same patient.
Thus, in vitro susceptibility of clinical isolates correlated
well with clinical outcome in immediate treatment. In
contrast, the long-term treatment did not appear correlated
with in vitro tests since relapses occurred even in patients
harboring susceptible strains [9]. Correlation between the
clinical outcome and in vitro susceptibility tests was also
observed in Indian ﬁeld isolates [6]. A correlation was also
found between treatment failure in patients, the IC50 of
L. donovani promastigotes and the lack of response in the
animal model suggesting the use of the IC50 study as a
reliable test for resistance [45]. In an area highly endemic
for visceral leishmaniasis in India, a double-blinded survey
was performed in which intracellular amastigotes IC50 was
determined for the ﬁrst group of patients, whereas in the
second group, patients were treated without testing the
parasite sensitivity. Results showed a statistically signiﬁcant
improvement of cure rate reaching 86% in the ﬁrst group
compared to 35% in patients treated with SbV without in
vitro tests [46].
Nevertheless, clinical outcome and in vitro susceptibility
tests can be contradictory as shown for L. donovani clinical
isolates tested for their sensitivity to SbV and SbIII. Indeed,4 Journal of Tropical Medicine
Rijal et al. identiﬁed three proﬁles of resistance: strains
sensitive to both forms of antimony, SbV resistant strains
but SbIII sensitive and ﬁnally strains refractory to the two
compounds. All patients unresponsive to treatment were
infected with strains resistant to pentavalent antimony but
this phenotype was also found in patients who responded
to treatment. Some strains harvested from cured patients
displayed in vitro resistance to SbIII. Finally, out of 3 patients
whose strains were resistant to both SbV and SbIII, only one
experienced treatment failure [47]. The same discrepancies
were observed in a study performed on new world clinical
strains [48]. These surveys suﬀer most from a lack of
standardization regarding the criteria for treatment failure,
the diﬀerence of resistance threshold, and the patients’
population under study.
2.3. Molecular Determination of Resistance: Main Techniques.
As mentioned above, these tests are carried out on selected
in vitro mutants, on clinical human isolates, or on strains
aﬀecting other vertebrates such as L. tarentolae, a species
widelyusedinvitro.Thetwoparasitestagesareexaminedbut
mostly promastigotes. Mutants are selected by exposure of
parasites to increasing concentrations of the drug. Revertant
strains are obtained by successive passages in culture of the
resistant strain without drug exposure.
2.3.1.GeneAmpliﬁcationinLeishmania . Geneampliﬁcation
was the ﬁrst molecular resistance mechanism identiﬁed in L.
major resistant to methotrexate (MTX) and displayed by the
presence of H-circle [49]. The presence of circular amplicons
in Leishmania is often the consequence of homologous
recombination between repeated sequences. These events
seem to be frequent in Leishmania and early associated to
resistance phenotype. The presence of these elements has
also been found in strains selected for other molecules
unrelated to MTX as not only primaquine, and terbinaﬁne,
vinblastine but also arsenicals [50, 51]. This ampliﬁcation
may concern preexistant or novel H-circles [52, 53]. Their
presence has been documented for wild strains of L. major
and L. tarentolae. In addition to multidrug-related protein
A (MRPA), two other genes have been identiﬁed within
the H-circles: pteridine reductase 1 (PTR1) and H region
terbinaﬁne-associated resistance gene (HTBF) [54, 55].
Historical techniques for DNA and RNA analysis (South-
ern and Northern blotting) are now replaced by quantitative
real time PCR (qPCR) or Reverse Transcription qPCR (RT-
qPCR). qPCR is performed in order to compare ampliﬁca-
tion rate of a target gene between susceptible and resistant
Leishmania strains. Results are expressed as threshold cycle
(CT) and need to be standardized by using a housekeeping
gene in the studied strains hence revealing possible gene
ampliﬁcation in resistant strain compared with wild type
one [56]. Gene ampliﬁcation can also be established by
Southern blot by hybridization of gene of interest with
its complementary probe [57, 58]. Quantitative reverse
transcription PCR (qRT-PCR) is an approach used in this
context to highlight gene overexpression of RNA which can
be independent of ampliﬁcation [59].
Recent advances in genomic approaches of Leishmania
resistance were brought by DNA microarray technique con-
comitant with whole genome sequencing of L. infantum and
L. major enabling an exhaustive prospection of diﬀerences
between resistant and susceptible strains at gene level. Diﬀer-
ential expression among the two strains is easily recognized
by disposing of cDNA genomic bank and diﬀerent genetic
markers. DNA microarray technology allows testing a large
setofgenesattheDNAorRNAlevelsinauniqueexperiment
and so is useful as screening test [60].
2.3.2. Functional Cloning. Functional cloning of cosmid
bank is a widely used technique for determination of genes
functions. Cosmids harbouring a resistance marker such
as hygromycine are transfected in Leishmania. This marker
allows the selection of strains hosting the cosmid. Afterwards
parasites are exposed to the investigated drug, such as
antimonials [61]. There are two approaches for functional
cloning depending onexpectedeﬀect,dominantpositive one
and dominant negative one. In case of dominant positive
cloning, the cosmid is transfected into a wild-type strain,
and acquisition of a new function such as drug resistance
is analyzed. By contrast in dominant negative selection
resistant strains are transfected with the cosmid in order
to obtain a reversal of resistance [62]. Once identiﬁed,
cosmid of interest is retransfected in the strain under
study to conﬁrm the phenotype. Subsequently, the cosmid
is sequenced and blasted with genomic bank in order to
identify the resistance gene. In addition, this gene could
be transfected into wild type strain to ascertain its role in
resistance.
2.3.3. Transfection and Deletion Experiments. Gene trans-
fection is used to identify a new phenotype or a new
functionality such as resistance. The strain transfected with
gene of interest is compared to the same strain transfected
with vector only, so keeping the original phenotype [63].
Proteinlocalizationcanalsobedeterminedbycotransfection
experiments with green ﬂuorescent protein (GFP) [64].
Phenotype deletion at genomic scale is carried out by
gene knockout (KO) approach. As Leishmania is a diplo¨ ıd
organism, two strategies are possible: a single allele KO
resulting in a decrease in targeted functionality [61]a n d
double knockout leading to phenotype suppression. This
technique is uncommon because of the diﬃculty to obtain
ad o u b l eK O .
2.3.4. Gene Polymorphism and Resistance. Isolates of L.
donovani have been studied on the basis of their genetic
diversities, variations, and molecular phylogenetic structure
using ﬁngerprinting approach-ampliﬁed fragment length
polymorphism (AFLP) and identiﬁed a polymorphism
percentage of 55%. Speciﬁc markers have been identiﬁed
showingadiﬀerentexpressioninresistantL.donovanistrains
[65].
Genetic studies, analyzing the whole genome, would
present the advantage of searching gene of interest without
any previous choice concerning their function. These studiesJournal of Tropical Medicine 5
need a very good deﬁnition of phenotype to lead to
signiﬁcant results.
2.3.5. Pulse Field Gel Electrophoresis. Pulse Field Gel Elec-
trophoresis (PFGE) can highlight diﬀerences at chromoso-
mal scale between two strains in addition to the possibility
of diﬀerentiation between linear and supercoiled DNA by
varying pulse time [57].
2.4. Protein Level. Proteomic approach was initially reduc-
tive but last years global techniques as two-dimensional
electrophoresis and more recently mass spectrometry oﬀer
a global analysis of cell proteome.
2.4.1. Immunoblotting. Proteomic approach can be per-
formed by immuno-enzymatic assays such as Western blot
(WB), a semiquantitative technique that can reveal the
presence of a protein and compare its relative abundance
to other strains based on the band intensity [57]. Necessity
of renaturation of protein during tranfert and availability of
speciﬁc antibodies constitute the main limiting factors.
2.4.2.FlowCytometry. Flowcytometrywasusedintwoaims:
as a tools for Leishmania quantiﬁcation in the last stage of
sensitivity testing of infected cells and more interestingly for
functional analysis of drugs transporter by using ﬂuorescent
drug analogs and speciﬁc inhibitors [31]. Speciﬁc inhibitors
are commonly used for two purposes: the ﬁrst is in vitro
study of inhibiting an enzyme supposed to participate in
resistance phenotype; the second is withdrawal of resistance
proﬁle in animal model using such inhibitor in combination
with antimonials.
2.4.3. Mass Spectrometry. This technique took an important
place in recent years in proteomic studies. Its ﬁeld of interest
can range from screening of proteins giving an overall
assessment of the diﬀerences that may exist between two
strains to the sequencing of a protein. This approach is
usually preceded by a two-dimensional electrophoresis or by
liquid chromatography [66].
2.5. Metabolites Determination. Several techniques are used
tostudydrugsuptakeandaccumulationinLeishmania.They
are also utilized to determine concentration of metabolites
involved in drug detoxiﬁcation.
2.5.1. High-performance Liquid Chromaography. High-
performance liquid chromaography (HPLC) was mainly
used for isolation, identiﬁcation, and quantiﬁcation of drug
and/or thiols metabolites [57, 63].
2.5.2. Injection-Coupled Plasma Mass Spectrometry.
Injection-coupled plasma mass spectrometry (ICPMS)
is used in Leishmania resistance surveys to measure
diﬀerences in uptake and accumulation of SbV or SbIII
depending on strain sensitivity or its stage [67].
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Figure 1: Main pathways involved in Leishmania resistance.
All these techniques allowed to discover and investigate
one or several mechanisms related to Leishmania drug resis-
tance. They involve drug entry, thiol metabolism pathway,
drug transport and sequestration, programmed cell death
and other minor mechanisms or cofactors as illustrated in
Figure 1.
3.Leishmania Antimony Resistance
Is Multifactorialand
Involves Numerous Pathways
Resistance pathways in Leishmania share some common
features with other microorganisms such as drug entry, drug
metabolism, eﬄux and/or sequestration, programmed cell
death along with action on host cell.
3.1. Drug Entry. The route of entry of antimonials is still
unclear and does not appear to be the same for SbV
and SbIII. Accumulation of SbV and SbIII by antimonials
sensitive and resistant strains of diﬀerent Leishmania species
showed that both axenic amastigotes and promastigotes
accumulated both forms of antimony using diﬀerent carriers
[67, 68]. SbIII entry is in part dependent on a parasitic
plasma membrane protein, aquaglyceroporine (AQP1), also
involved in the entry of other metbolites. AQP1 cloning
and transfection in L. infantum, L. major, and L. tarentolae
promastigotes expressing luciferase gene and infecting THP1
cell line showed increment of their susceptibility to SbIII and
AsIII.Aregainin susceptibility wasnoticed aftertransfection
of AQP1 to in vitro selected mutants for SbIII resistance.
These strains showed faster incorporation of SbIII and
AsIII with 20- to 50-fold higher steady state accumulation
amount compared to those transfected with the vector only.
Amastigotes harvested from a resistant L. donovani ﬁeld
isolate recovered susceptibility after being transfected. Single
allele knock-out in a L. major strain had led to a 10-fold
decrease in its susceptibility, highlighting the signiﬁcance6 Journal of Tropical Medicine
of AQP1 amount in resistance phenotype [61]. There was
no diﬀerence in AQP1 gene copy number between resistant
and susceptible strains. In strains exhibiting decreased
susceptibility to SbIII, this protein was underexpressed and
a correlation was found between accumulation rate of SbIII
and RNA expression level of AQP1 [62]. The AQP1 gene was
found to be underexpressed in antimony resistant clinical
isolates from Nepal in comparison with susceptible ones
[69]. The composition of the amino acid sequence of AQP1
appears to inﬂuence the incorporation rate of SbIII in
Leishmania. In fact, the replacement of alanine at position
163 by serine or threonine induced the decrease of the entry
of the active form of antimony [70]. Other mutations in the
sequence of this protein such as an alteration at Glu152 or
Arg230wereassociatedwithreducingSbIIIentry[71].These
mutations were not found in resistant Indian clinical isolates
with an underexpression of AQP1 [72]. Consequently, this
mechanism is probably the ﬁrst barrier that Leishmania
involves in order to counteract the action of antimonials and
induce resistance.
3.2. Drug Metabolism. It is generally accepted that to be
active on the parasite, the antimonial pentavalent form
(SbV) has to be reduced to its highly active trivalent one
(SbIII) [22, 35, 73–75] .T h es i t eo ft h i sr e d u c t i o na n d
its exact mechanism remain somewhat controversial but
thought to take place in both macrophage and parasite.
Major mechanisms are presented in Figure 2.
3.2.1. Macrophage-Dependent Reduction. Evidence of
macrophage involvement in reduction is that axenic
amastigotes are less susceptible to PentostamR than
intramacrophagic ones [35]. Furthermore, glutathione
(GSH) which is the major thiol of the host cell can reduce
SbV at 37◦C. However the eﬃciency of this reduction
decreases when pH increases from 3 to 8. In fact, at pH5,
a condition encountered in phagolysosome, this reaction
is more important than at pH7.2 (cytosol) and a little rate
of SbV conversion is found although the highest amount
of GSH is cytosolic [76]. Hence, it appears from these in
vitro experiments that reduction does occur in macrophage
but mostly in its acidic compartments such as endosomes,
lysosomes, and phagolysosome. Other macrophage cytosolic
thiols such as cystein and cysteinyl-glycin can also reduce
SbV at rates even higher than GSH either in acidic or
neutral pH conditions [77]. In a recent study, involvement
of macrophages in SbV reduction was assessed in the human
macrophage cell strain MM6. It has also demonstrated that
cellular amount of SbIII is related to that of SbV. The latter
seems to be in relation with extracellular SbV [78].
3.2.2. Intraparasitic Reduction. The sensitivity of Leishmania
depends on its ability to reduce SbV since antimonial
reduction activity of resistant L. donovani amastigotes was
impaired [68]. Reduction can be either enzymatic or nonen-
zymatic.
(1) Enzymatic Reduction. Two parasitic enzymes have been
identiﬁed as being involved in SbV reduction, a thiol
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Figure 2: Antimony metabolism and transport inside macrophage
and Leishmania. SbV: pentavalent antimony, SbIII: trivalent anti-
mony, AQP1: acquaglyceroporine 1, TSH: trypanothione, MRPA:
multidrug related protein A, MDR: multidrug resistance.
dependent reductase 1 (TDR1), and another one, called
LmACR2.
The sequence of TDR1 was identiﬁed in L. major by
in silico analysis, cloned, and the recombinant protein
showed high conversion rate of SbV to SbIII using GSH
as reducing agent. This enzyme was isolated from both
stages of L. major and 10 times higher level of TDR1 was
recovered from amastigotes than from promastigotes. Fur-
thermore its activity is noticeably greater than nonenzymatic
reduction [79]. LmACR2, an enzyme identiﬁed within L.
major genomic sequence was cloned and transfected into L.
infantum promastigotes: the derived amastigotes (infecting
THP1 macrophages) were more susceptible to Pentostam
compared to non transfected strain. Glutathione is also
required for LmACR2 activity. Transfection of this protein in
an Indian clinical isolate (L. donovani) induced sensitization
of this strain to a lower dose of Pentostam compared to
untransfected one [63].
(2) Nonenzymatic Reduction. This pathway involves parasite
thiols which are represented by cysteine, spermidine, GSH,
and trypanothione (TSH), the latter corresponds to the
major thiol of the parasite [80]. In vitro experiments
indicated that the SbV reducing activity of TSH was more
relevant at pH7 than at pH5 and in all cases faster than SbV
reduction with GSH [77]. Trypanothione results from the
combination of GSH and spermidin [80]. This metabolic
route involves two key enzymes, ornithine decarboxylase
(ODC) and gammaglutamylcysteinsynthase (GCS).Produc-
tion of thiols is crucial for the parasite in order to maintainJournal of Tropical Medicine 7
a reduced environment inside the cell that counters the
eﬀects of oxidative compounds such as antimonials. In fact,
the exposure of the parasite to heavy metals can lead to an
impairment of its redox potential causing an eﬄux of intra-
cellular thiols, the accumulation of intraparasitic disulﬁte,
and the inhibition of two enzymes: trypanothione reductase
and glutathione synthetase [81, 82]. Through conjugation to
SbIII, trypanothione intends preventing antimonials action.
Itcansobeinferredthatenhancementofthismachinerymay
resultinantimonyresistance.Infact,inL.tarentolaemutants
selected for AsIII resistance and shown to be cross resistant
to SbIII and SbV, thiols levels were higher than in wild type
strain mainly for TSH [33].
Molecular approaches pointed out an ampliﬁcation of
the GSH gene within a linear amplicon described in L.
tarentolae, selected for AsIII or SbIII resistance [17, 83].
Ampliﬁcation and overexpression of GSH are not always
correlated as shown for in vitro L. tarentolae selected for
SbIII resistance; GSH1 and GSH2 were overexpressed but no
ampliﬁcation was found for GSH2 and it was discrete for
GSH1 [83]. GSH1 overexpression was also found in clinical
isolates [57]. In L. tarentolae revertant strain, a drop of
GSH1 ampliﬁcation was associated to a signiﬁcant decrease
in thiol levels without reaching the basal one. Transfection
experiments carried out in this revertant strain with GSH
gene resume resistance proﬁle unlike wild type L. tarentolae
which remains susceptible despite displaying an increase in
thiols level that can be greater than that in resistant strains to
AsIII [17]. Therefore, the intracellular TSH level is crucial to
conferresistancepatternbutisnotsuﬃcientalonetoprovide
it. The level of thiols measured in L. donovani promastigotes
was signiﬁcantly higher in resistant strains with increased
metabolic turnover and faster regeneration of thiols in order
to counteract the production of ROS by antimonials. This
eﬀect is abolished by H2O2 which causes a depletion of thiols
thus restoring the eﬃciency of antimony [84].
For ODC, an overexpression without ampliﬁcation was
found in both L. tarentolae AsIII resistant and revertant
strains and for in vitro selected L. tropica and L. mexicana.
Since there was not gene rearrangement nor increased trans-
lation, this overexpression in the absence of ampliﬁcation
may be the consequence of an enhanced RNA stability [85].
In clinical strains, ODC gene was found ampliﬁed; this
amplicon was not extrachromosomal and protein amount
was increased [57]. In clinical isolates, ODC overexpression
was found in resistant strains of L. braziliensis and was
associated with GSH overexpression in L. donovani [57, 86].
Speciﬁc inhibition of GSH and ODC with buthionine
sulfoximine (BSO) and diﬂuoromethylornithine (DFMO),
respectively, further supported their role in resistance. This
suppression resulted in a partial reversal of resistance in
resistant strains and in a decrease in TSH eventhough
remaining at residual level higher than in wild type strains
[16, 32, 37, 85]. Reversal of resistance was also obtained
by BSO in unresponsive L. donovani and L. tropica clinical
isolates [5, 39].
Inhibition of GSH synthesis by BSO was also tested
in vivo in mice infected with resistant and susceptible
strains of L. donovani. The combined treatment SbV + BSO
signiﬁcantly increased sensitivity and decreased resistance,
respectively [39]. However, BSO had no eﬀect on L. pana-
mensis clinical strains resistant to SbV [37].
As reported above, intracellular glutathione is crucial for
cell survival by maintaining a redox balance and protection
against toxic agents that cause oxidative or chemical stress.
Impairment of production of GSH is toxic to cells and
its inhibition has been successfully used to increase the
sensitivity of number of intracellular pathogens and cancer
cells to diﬀerent drugs. Infection of mice with SbV sensitive
L. donovani strains is associated with increased macrophage
GCSmRNAunlikeresistantstrainswhichinduceareduction
in intramacrophagic expression of GCS which leads to a loss
ofGSHandgeneratesanoxidativeenvironmentintothehost
cell. Consequently, the reduction of SbV to its highly active
SbIII is diminished in macrophage. In contrast, these same
resistant strains display an overexpression of GCS compared
to susceptible ones leading to a higher rate of thiols in the
parasite in order to compensate an oxidizing environment
generated in macrophage [87].
In L. infantum axenic amastigotes selected for SbIII,
SAHH gene, which is responsible for the conversion of
S adenosyl homocystein to homocystein, the cystein pre-
cursor was overexpressed. Interestingly, cystein which is a
glutathione precursor was the only thiol with increased
concentrationinthisstudy.SAHHwasalsoampliﬁedinSbIII
resistant L. tarentolae [83].
3.3. Drug Transport. In several microorganisms, membra-
nous transport plays a major role in drug resistance. ATP
Binding Cassette (ABC) family is a set of proteins involved
in resistance either by drug eﬄux or by its sequestration.
This eﬄux pumps system was ﬁrst described in tumor cells,
and the derived phenotype was named multidrug resistance
(MDR) resulting in refractoriness to chemotherapy. In
Leishmania,8 subfamilies ofABCtransporters genes, present
among 19 diﬀerent chromosomes, were identiﬁed when L.
major whole genome was compared with established ABC
proteinssequences[59].Amongthese,twosubclassesofABC
transporters seem to be involved in Leishmania resistance:
(1) carriers with high similarity to P-glycoproteins in
mammals that confer an MDR phenotype similar to
that seen in cancer cells,
(2) homologoustotheMultidrugResistance-relatedPro-
tein (MRP) in humans [88].
3.3.1. MDR. MDR proﬁle was found in resistant strains of
Leishmania and the MDR1 gene was ampliﬁed in mutants
selected for resistance to vinblastine, daunomycin, or to
puromycin [89–92]. MDR-class transporters are involved in
extrusionofhydrophobicmoleculesbutnothydrophilicones
as SbIII. Indeed, this eﬀect has not been demonstrated for
antimonials.
3.3.2. MRPA. MRPA formerly called PGPA for P-glycopro-
tein A is the most studied ABC transporter in Leishmania
and its role in resistance is well documented in vitro8 Journal of Tropical Medicine
[93]. MRPA gene is often located on an ampliﬁed H-
circle extrachromosomal DNA [21, 83, 88, 93–95]w h i c h
initially belongs to a locus in chromosome 23. This locus
is ﬂanked at each side by repeated sequences of 1389bp
that present a sequence homology of 100% in a L. infantum
strain selected for SbIII resistance [60]. These repeats were
also found on the same chromosome of L. major and
L. braziliensis [96]. However, in L. mexicana selected for
AsIII resistance, it was located in a linear amplicon [95].
MRPA gene is frequently ampliﬁed/overexpressed in strains
resistant to heavy metals [60, 83]. The level of resistance
is associated with this ampliﬁcation as demonstrated by a
comparative study between in vitro selected L. major and
L. braziliensis strains to antimonials [96]. In fact, resistance
was associated to H-circle ampliﬁcation in L. major but not
in L. braziliensis and the latter remained signiﬁcantly more
sensitive to antimony. Similarly, decreased ampliﬁcation was
observed in revertant strains. Initially susceptible strains
transfected with MRPA gene acquire a certain level of
resistancetoSbIIIorAsIIIbutthislevelisvariabledepending
on species even if equal band intensity can be found in
WB for MRPA recombinant protein [95, 97, 98]. This
variability can be explained by an interspecies diﬀerence in
basal level of thiols. Evidence of combined action between
MRPAandthiolsinheavymetalsresistancewasconﬁrmedby
cotransfection experiments of MRPA and GSH genes which
confer resistance in wild type L. tarentolae and restore a high
resistance level in revertant strain unlike GSH transfection
alone [17]. Unlike classical ABC proteins, MRPA does not
act by eﬄux at the plasma membrane. In fact, this protein is
located in an intracellular compartment close to the ﬂagellar
pocket of the parasite recognized as the site of endocytosis
andexocytosisandactsbythesequestrationoftheSbIII-TSH
complex since free SbIII or AsIII is not transported by MRPA
[62, 78]. Therefore, thiols act by two opposite mechanisms:
on one hand, they are involved in drug activation and
on the other, in its inactivation via its sequestration. In
parallel with drug sequestration, MRPA ampliﬁcation seems
to cause a decrease in drug entry rather than increasing its
eﬄux [99]. This can be explained by a possible dominant
negative role played by MRPA on membrane proteins.
Plasma membrane eﬄux mechanism was demonstrated in
Leishmania in membrane-enriched everted vesicles of L.
tarentolae in which an ATP calcium-dependent protein was
involved in AsIII-GSH transport not mediated by MRPA.
In fact, double knock-out of MRPA gene did not alter this
transport which was inhibited to some extent by Pentostam
indicating competition between the two related metals. In
addition, the activity of this transporter is not increased in
membranesfrommutantsthatoverexpressMRPAsuggesting
that this thiol X eﬄux pump is encoded by another gene.
Nevertheless, no protein was yet identiﬁed [100].
Functional studies of the ABC family pumps were per-
formed on clinical isolates of L. donovani (promastigotes and
axenic amastigotes) using rhodamine123 (R123) as substrate
for MDR, calcein for MRP, and by employing speciﬁc
inhibitors. The R123 accumulation was found greater in
resistant strains and its rate was not modiﬁed by verapamil,
a speciﬁc inhibitor of MDR, suggesting the absence of a
classical MDR activity. The accumulation of calcein was
lower among these resistant strains for both promastigotes
and axenic amastigotes. Use of probenecid, an inhibitor
of MRP, did not lead to a signiﬁcant increase in calcein
unlike ATP depletion indicating the existence of an MRP-
like pump more active in resistant isolates [101]. The role
of MRPA and the level of resistance depend on the rate
of residual SbIII as demonstrated in a study that initially
showed no correlation between the in vivo eﬃcacy of
SbV and the residual SbIII in parasite but highlighted the
importance of this residual rate for the action of MRPA.
Indeed, although strains that overexpress MRPA were all
resistant to SbIII, cross-resistance to SbV was observed only
in strains that exhibited a high SbIII residual rate, indicating
that this refractoriness was directed against the antimony
t r i v a l e n tf o r m[ 102]. Leprohon et al. found that MRPA was
overexpressed in SbIII resistant L. infantum, compared to
wild type by microarray approach. Interestingly, two other
proteins of the ABC family were overexpressed, namely,
ABCA3 and ABCH1. Identical results were obtained in
anotherindependentlyselectedstrain.However,inwild-type
strains,onlyMRPAtransfectionconfersSbIIIresistance[59].
Implication of ABCA3 in vesicular traﬃcking and exocytosis
pathway supports an indirect implication in Leishmania
resistance [103].
All these proteins were located in intracellular compart-
ments. Their role in resistance to antimonials was investi-
gated in a revertant strain of L. tarentolae. Only transfections
of ABCC4-GFP and ABCC5-GFP were accompanied with a
two-fold increase of resistance level [64].
3.3.3. Other ATP-Dependant Transporters. Other proteins of
the MRP subfamily of ABC have been identiﬁed as PGP
B, C, D, and E. However, single transfection of their genes
does not confer resistance [88]. The role and action of these
proteins remain unknown, buttheir sequencesimilarity with
MRPA indicates that they may correspond to membrane
transporters involved in antimonials eﬄux. Recently, a
second protein belonging to the ABC family transporters,
and named PRP1, was identiﬁed by cloning after selection
by pentamidine. This protein confers cross-resistance to
antimonials [108].
Some genes identiﬁed in vitro as involved in resistance to
antimonials were investigated in clinical isolates from Sudan
and France [56]. MDR1 was ampliﬁed in 65% of isolates
and was the only statistically associated with L. infantum.
Ampliﬁcation of MRPA in concomitance with GSC was
observedinsomestrainsconﬁrmingthejoint actionofthiols
metabolism and sequestration of conjugated antimony. This
ampliﬁcation is stable in successive samples for the same
patient. Nevertheless, it was not possible to establish a corre-
lation between therapeutic response and gene ampliﬁcation
observed in this survey since the French patients were treated
with liposomal amphotericin B while the clinical data were
lacking for Sudanese isolates. However, it supported the
presence of an ampliﬁcation of some genes identiﬁed in vitro
as taking part in resistance. The singularity of this study is
the presence of an ampliﬁcation of the MDR1 gene which is
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molecules other than heavy metals. The signiﬁcance of this
issue remains diﬃcult to elucidate and we can only speculate
on the role of MDR1 in antimony resistance in clinical
isolates. This phenomenon can be explained by adaptative
functions of the parasites when exposed in vivo to drugs
used for treatment of another disease. This drug can select
in Leishmania a new function, such as MDR1 ampliﬁcation
in this case, without any linkage to antimony therapy. DHFR
gene is another illustration of this phenomenon. This gene
is related to folates pathway and antifolates are used in
several aﬀections such as malaria where DHFR is ampliﬁed
in Plasmodium resistant strains [109]. Although antifolates
are not used in Leishmania treatment, ampliﬁcation of
DHFR gene occurs in vitro after methotrexate selection and
in clinical strains [56, 83]. In other situations, selection
by other molecules can lead to cross-resistance. Indeed,
miltefosine, a drug recently introduced in antileishmanial
therapy, has plasma membrane as targets [110] and it was
suggested that antimony resistant Leishmania also shows
membranemodiﬁcations[111].Combinedwithantimonials
wide use in some endemic areas, this mode of action led to
cross-resistance between these two molecules [112]. Table 1
summarizes the most important molecular targets identiﬁed
either in in vitro selected mutants or in ﬁeld isolates of
Leishmania.
3.4. Programmed Cell Death. A comparative proteomic anal-
ysis between two L. donovani Indian clinical isolates resistant
a n ds u s c e p t i b l et oS b V[ 66] identiﬁed proteins having al-
ready known roles in programmed cell death (PCD) as the
14-3-3 protein present in higher quantities in the resistant
strain, and which belongs to a family of conserved pro-
teins able to bind other phosphorylated proteins involved
in apoptosis [113]. Heat Shock Proteins (HSPs) are also
involved in PCD by modulating some steps in the apoptosis
pathway [114]. In fact, Antimonials induce the production
of a variety of HSPs (HSP70, HSP81, and HSP65) and
their role is supposed to be protective against the toxic
eﬀect of these drugs. HSP70 and HSP83 were overexpressed.
Transfection of a cosmid library in Leishmania parasites
and their selection with SbIII identiﬁed in resistant strains
a cosmid containing HSP70 and HSC70. The protein
expression of HSP70 increased when concentration of SbIII
was incremented. Overexpression of HSP70 was found in
revertant strains suggesting its stability. However, transfec-
tion experiments of HSP70 or HSC genes did not give rise
to any resistance thus assuming a minor role in resistance.
Similarly, Brochu et al. showed that level of HSPs of diﬀerent
molecular weights is increased in the presence of arsenicals.
However,transfectionofHSPgenedoesnotconferresistance
directly but rather increases parasite tolerance to heavy
metals[115].Smallkinetoplastidcalpain-relatedprotein1.14
(SKCRP1.14), which was underexpressed in L. donovani
resistant strain [90], is often associated to other proteins
identiﬁed as eﬀectors of PCD in kinetoplastidae [116]. Thus,
it is conceivable that the process of apoptosis in resistant
strains is impaired. This is corroborated by evidence of
reduced DNA fragmentation and formation of bridges in
resistant strains compared to susceptible ones.
3.5. Other Mechanisms and Cofactors of Resistance. Trypare-
doxin peroxidase (Trper), an enzyme responsible for perox-
ides ions detoxiﬁcation in Leishmania, also plays a role in
antimonial resistance as shown in L. donovani promastigotes
and amastigotes transfected with this protein. In fact,
either in vitro selected strains or ﬁeld isolates became less
susceptibletoSbIII[105,106].Likewise,theresistanceproﬁle
was also demonstrated in resistant mutants of L. tarentolae
strains by overexpression of the recombinant protein in
initially susceptible strains [107].
Histones H4, H2A, and H1 showed diﬀerential expres-
sion pattern between susceptible and resistant strains of
L. donovani clinical isolates [117]. Nevertheless, H2A gene
transfection in L. donovani susceptible strains displayed
no signiﬁcant increase in the ED50 for SbIII. Diﬀerential
expression also concerned MAPK, a mediator which plays an
important role in intracellular multiplication of the parasite,
the morphogenesis of the ﬂagellum and consequently in the
virulence of the parasite during host infection [117–119].
LinJ05 V3.0830 was 4 times overexpressed in L. infantum
resistant strains selected for SbIII resistance. However,
transfection experiments in sensitive and revertant strains
indicated no signiﬁcant change in sensitivity [60].
Leishmania synthetizes phosphoproteoglycans (PPGs)
that are secreted or present at the parasite membrane in
the two stages. These proteins play an important role in
parasites survival [120]. Quantitative analysis highlighted
greater amount of PPG in resistant strains.
Various other proteins were overexpressed in resistant
clinical isolates of L. donovani at membrane and cytosolic
levels such as GPI transaminase protein, a cysteine-rich
leucine protein, a 60S ribosomal protein L23a, prolifera-
tive cell nuclear antigen (PCNA), the alpha5 subunit of
the proteasome, carboxypeptidase, enolase, fructose-1,6-
bisphosphate aldolase, and a beta tubulin chain [121].
In L. infantum axenic amastigotes, proteomic approach
highlighted overexpression of arginosuccinate synthetase
and an underexpression of kinetoplastidae membrane pro-
tein (KMP-11) with an expression level correlated with
the resistance phenotype [122]. Other L. infantum strains
overexpressing a protein which belongs to the superfamily of
leucine-rich repeat (LRR) proteins, became resistant to SbIII
for axenic amastigotes and to SbV for intramacrophagic ones
[122].
3.6. Leishmania Resistant Strains Display Chromosomal
Changes. In an L. infantum mutant strain selected for SbIII
resistance, the expression of whole chromosomes was mod-
ulated, compared to the sensitive one [60]. Gene overex-
pression involved rather chromosomes 1, 11, and 25, in
opposition with chromosome 9, 12, and 32 where genes
were found underexpressed. Aneuploidy was also observed
in resistant strains. The rate of aneuploidy correlated with
the level of SbIII resistance. Interestingly, aneuploidy and
the presence of the circular amplicon carrying MRPA gene
disappeared in the revertant strain. However, haploidy for10 Journal of Tropical Medicine
Table 1: Relevant molecular targets involved in Leishmania antimony resistance.
DNA
ampliﬁcation
RNA
overexpression
RNA lowered
expression
Functional
cloning/
transfection
In vitro selected
mutants Field isolates References
MRPA ++++ ++++ + yes yes [21, 56, 83, 88, 93–
95, 97, 98]
GCS +++ +++ + [69] yes yes [56, 57, 69, 83
ODC ++ +++ + [69] yes [57, 69, 86
Tryr + yes [104]
Trper ++ + yes [105–107]
AQP1 ++++ + yes yes [61, 62, 69, 72]
LmACR2 + yes yes [63]
The number of “+” signs is relative to the importance of the mechanism. For GCS and ODC, RNA-lowered expression is found only in one survey.
MRPA: multidrug resistance related protein A.
GCS: gammaglutamylcystein synthase.
ODC: ornithine decarboxylase.
Tryr: trypanothione reductase.
Trper: tryparedoxin perxydase.
AQP1: aquaglyceroporin1.
LmACR2: Leishmania major antimony-arsenite reductase.
chromosomes 12 and 32 has persisted; this possibly explains
the remaining of resistance at residual level.
4.FieldIsolates CanExhibitResistance
Pattern Different from In Vitro Mutant
In a study on resistant ﬁeld isolates of L. donovani, increase
of thiols level was much lower than that observed in
mutant strains selected in vitro explaining in part the
higherresistanceobservedinmutantscomparedwithclinical
unresponsivestrains[45].Trypanothionereductasegenewas
2.5 times ampliﬁed in resistant isolates thus maintaining a
high level in thiols and counteracting the eﬀect of SbIII.
H o w e v e r ,G C Sg e n ew a sn o ta m p l i ﬁ e dl i k ei nL. tropica
clinical strains [104]. Unlike in vitro selected mutants in
which TSH level is usually increased, some clinical resistant
strains display cystein and GSH overproduction but not TSH
[57]. Ampliﬁcation of MRPA can also occur in susceptible
clinical strains [69]. As that of AQP1, GCS, and ODC
genes were surprisingly underexpressed in resistant strains in
intracellular amastigotes. This modulation was also observed
for GSC in the same proportions in promastigotes; it was
lower for AQP1 and absent in the case ODC. These ﬁndings
are in opposition with most studies on in vitro resistant
mutantsandothersurveysonclinicalisolates.Thisdiﬀerence
can be attributed at least for the in vitro mutant strains
to diﬀerent mechanisms depending on the used antimonial
form.Indeed,inthisstudyitwasobservedthatSbVexposure
ofamastigotesinducedanunderexpressionofAQP1involved
in the entry of antimony in the parasite cell, but also inhi-
bition of enzymatic and nonenzymatic pathways involved
in pentavalent compound reduction. This mechanism has
been described in axenic amastigotes of L. donovani [68].
The number of copies of AQP1 gene may not correlate with
the level of expression as determined in L. donovani resistant
clinicalisolates,whichdisplayedloweredSbIIIaccumulation,
an underexpression of AQP1, but increased copy number
of its gene [72]. Inconsistency between in vitro resistance
tests and clinical outcome was also found in cutaneous
leishmaniasis isolates from Peruvian subjects [123]. Some
molecular targets were tested in promastigotes ofamerican
cutaneous leishmaniasis clinical isolates (L. braziliensis, L.
guyanensis). For L. braziliensis there was no diﬀerence in
expression for MRPA, GSH, trypanothione reductase, and
TDR1 in relation to treatment issue, while for L. guyanensis,
GSC gene was overexpressed in strains that caused treatment
failure [124].
Recently, an ampliﬁed sequence of 1254Kb was found
in L. donovani resistant ﬁeld isolates [58]. Hybridization
experiments have shown that this sequence did not match
any gene of ABC family or with other genes involved in
resistance. This sequence does not contain transmembrane
domain eliminating a possible role in eﬄux. However,
antibodies against the recombinant protein of this sequence
allowed assessing its membrane localization. The functional
study of this sequence conﬁrmed the absence of an MDR-
like pump that can be inhibited by verapamil or an MRP-like
pump.
Anotherexperimentusingintramacrophagicamastigotes
labeled with luciferase from susceptible and resistant L.
donovani clinical isolates showed that refractory clinical
strains to SbV displayed also in vitro resistance to this
compound. This strain was also signiﬁcantly more resistant
to SbIII than the susceptible one that allowed performing
experiences on promastigotes, easier to carry on. Genes
usually involved in in vitro resistance as AQP1, MRPA, or
GSH were not modulated in the resistant strain [66].
5. Conclusion
Antimonials remain the ﬁrst line treatment of leishmaniasis
in medical and veterinary ﬁelds and the emergence andJournal of Tropical Medicine 11
spreading of resistance is still an important public health
problem.
This phenomenon is complex and multifactorial. Exper-
imental studies have pointed out the role of numerous
mechanism involved in resistance. Field studies gave partial
information and deﬁnition of the resistant phenotypes
appeared to be diﬃcult because of the inﬂuence of host
factors and lack of exhaustivity.
In vitro sensitivity testing on infected cells remains the
better global estimation of Leishmania resistance and sub-
stitutive, informative, molecular tests are needed. All these
observations lead to a better understanding of resistance
mechanisms in Leishmania. Progress is undeniable; however,
the discrepancies between in vitro and clinical resistance
remain numerous, even for surveys held for clinical isolates
of the same species in adjacent geographic areas. This review
illustrated the diﬃculties to identify markers of resistance
that can be standardized with a test easy to implement,
replacing the time consuming determination of IC50 in the
amastigote-macrophage model. Additional work, focusing
on search for reliable molecular markers, would be valuable
for the community.
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